The phase 3 clinical trial program included 2 identical, multicenter, double-blind, and placebo-controlled trials of the BACE inhibitor intended for the treatment of early Alzheimer disease.
from Front page feed https://ift.tt/2I8BeL5
from Front page feed https://ift.tt/2I8BeL5
Comments
Post a Comment